Product Specification Sheet

Product Name: Abiraterone

Catalog Number: C2247-2 (powder)
C2247-2s (10mM in DMSO)

Package Size: 2 mg



Technical information:

Chemical Formula:	$C_{24}H_{31}NO$
CAS #:	154229-19-3
Molecular Weight:	349.51
Purity:	>98%
Formulation:	White solid
Solubility:	Soluble in DMSO up to 50 mM
Chemical Name:	(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
Storage:	Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Handling:

- For C2247-2 (powder), add 572 µL of DMSO to make 10 mM solution.
- For C2247-2s, before open the vial, centrifuge the vial at 500rpm x 1 min in a 50 mL conical tube to ensure full sample recovery.

Biological Activity: Abiraterone is a potent steroidal inhibitor against cytochrome P450 17alpha-hydroxylase-17,20-lyase (CYP17) with an IC50 at 4 nM. It was approved by the FDA in April 2011 to treat castration-resistant prostate cancer. A phase I/II clinical trial evaluating abiraterone acetate in advanced breast cancer patients are also underway. In preclinical studies, abiraterone has demonstrated the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes.

Reference:

1. Attard G et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742-8.
2. Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563-71.

For Technical Support: technical@cellagentech.com

For research use only, not for clinical or diagnostic use.